These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20598452)

  • 1. Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer.
    Small W; Mulcahy MF; Rademaker A; Bentrem DJ; Benson AB; Weitner BB; Talamonti MS
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):476-82. PubMed ID: 20598452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
    Small W; Berlin J; Freedman GM; Lawrence T; Talamonti MS; Mulcahy MF; Chakravarthy AB; Konski AA; Zalupski MM; Philip PA; Kinsella TJ; Merchant NB; Hoffman JP; Benson AB; Nicol S; Xu RM; Gill JF; McGinn CJ
    J Clin Oncol; 2008 Feb; 26(6):942-7. PubMed ID: 18281668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.
    Spry N; Harvey J; Macleod C; Borg M; Ngan SY; Millar JL; Graham P; Zissiadis Y; Kneebone A; Carroll S; Davies T; Reece WH; Iacopetta B; Goldstein D
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1438-46. PubMed ID: 18164859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer.
    Robertson JM; Margolis J; Jury RP; Balaraman S; Cotant MB; Ballouz S; Boxwala IG; Jaiyesimi IA; Nadeau L; Hardy-Carlson M; Marvin KS; Wallace M; Ye H
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e187-92. PubMed ID: 21549514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
    Crane CH; Winter K; Regine WF; Safran H; Rich TA; Curran W; Wolff RA; Willett CG
    J Clin Oncol; 2009 Sep; 27(25):4096-102. PubMed ID: 19636002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
    Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
    World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
    Van Buren G; Ramanathan RK; Krasinskas AM; Smith RP; Abood GJ; Bahary N; Lembersky BC; Shuai Y; Potter DM; Bartlett DL; Zureikat AH; Zeh HJ; Moser AJ
    Ann Surg Oncol; 2013 Nov; 20(12):3787-93. PubMed ID: 23904005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
    Ch'ang HJ; Lin YL; Wang HP; Chiu YF; Chang MC; Hsu CH; Tien YW; Chen JS; Hsieh RK; Lin PW; Shan YS; Cheng AL; Chang JY; Whang-Peng J; Hwang TL; Chen LT
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e749-57. PubMed ID: 21420250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
    Ikeda M; Okada S; Tokuuye K; Ueno H; Okusaka T
    Br J Cancer; 2002 May; 86(10):1551-4. PubMed ID: 12085203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer.
    Hunter KU; Feng FY; Griffith KA; Francis IR; Lawrence TS; Desai S; Murphy JD; Zalupski MM; Ben-Josef E
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):921-6. PubMed ID: 22208966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.
    Sohal DP; Metz JM; Sun W; Giantonio BJ; Plastaras JP; Ginsberg G; Kochman ML; Teitelbaum UR; Harlacker K; Heitjan DF; Feldman MD; Drebin JA; O'Dwyer PJ
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1485-91. PubMed ID: 23532207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study.
    Koukourakis MI; Giatromanolaki A; Tsoutsou P; Lyratzopoulos N; Pitiakoudis M; Kouklakis G; Chloropoulou PA; Manolas K; Sivridis E
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):492-8. PubMed ID: 20584585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer.
    Kurt E; Kurt M; Kanat O; Cetintas SK; Aygun S; Palazoglu T; Ozkan L; Evrensel T; Kaya E; Manavoglu O
    Tumori; 2006; 92(6):481-6. PubMed ID: 17260487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
    Kindler HL; Friberg G; Singh DA; Locker G; Nattam S; Kozloff M; Taber DA; Karrison T; Dachman A; Stadler WM; Vokes EE
    J Clin Oncol; 2005 Nov; 23(31):8033-40. PubMed ID: 16258101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
    Kornek GV; Pötter R; Selzer E; Schratter A; Ulrich-Pur H; Rogy M; Kraus G; Scheithauer W
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):665-71. PubMed ID: 11172947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
    Kindler HL; Niedzwiecki D; Hollis D; Sutherland S; Schrag D; Hurwitz H; Innocenti F; Mulcahy MF; O'Reilly E; Wozniak TF; Picus J; Bhargava P; Mayer RJ; Schilsky RL; Goldberg RM
    J Clin Oncol; 2010 Aug; 28(22):3617-22. PubMed ID: 20606091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
    Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.
    Mahadevan A; Jain S; Goldstein M; Miksad R; Pleskow D; Sawhney M; Brennan D; Callery M; Vollmer C
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):735-42. PubMed ID: 20171803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
    Ko AH; Dito E; Schillinger B; Venook AP; Xu Z; Bergsland EK; Wong D; Scott J; Hwang J; Tempero MA
    Invest New Drugs; 2008 Oct; 26(5):463-71. PubMed ID: 18379729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.